Cutaneous immediate and late phase reactions to schistosomin in schistosomiasis patients.

Cutaneous immediate and late phase reactions (LPR) to schistosomin were studied in 29 patients with schistosomiasis mansoni. In 12 of these patients, the determination of total and specific serum IgE by immunoenzymatic method against schistosome antigen was carried out using serum samples obtained on the same day as the cutaneous tests. Skin biopsies were taken from 4 typical LPRs. Immediate reactions occurred in all except one and LPRs in 12 (41.3%). Patients with positive cutaneous reactions had highe levels of specific serum IgE against schistosome antigen. Histopathological studies showed a moderate exudate consisting mainly of neutrophils (60%) and eosinophils (40%). LPRs in schistosomiasis have the same characteristics reported in the medical literature in relation to time of appearance, morphology and histopathology. The immunopathogenic role played by LPRs in the patients remains to be clarified.

Colchicina na doença hepática crônica de etiologia alcoólica. Estudo duplo-cego, randomizado, de seus efeitos sobre os níveis séricos das proteínas plasmáticas e evoluçäo clínica dos pacientes / Colchicine in chronic liver disease of alcoholic etiology. Double-blind, randomized study of its effects on the serum levels of plasma proteins and clinical evolution of the patients

Pacientes portadores de hepatopatia crônica de etiologia alcoólica, quando tratados com colchicina durante período de 12 meses, apresentaram índices de recuperaçäo dos níveis plasmáticos de albumina e protrombina significantemente superiores aos de pacientes fazendo uso de placebo. Entretanto, nenhuma diferença estatística pôde ser observada entre os dois grupos quanto à taxa de mortalidade e de admissäo hospitalar dos pacientes, no período estudado. OBJETIVO. Analisar a evoluçäo clínica e os níveis plasmáticos de albumina, pré-albumina, transferrina e protrombina em portadores de hepatopatia crônica alcoólicaem uso de colchicina ou placebo, durante período de 12 meses. MÉTODOS. em um estudo duplo-cego, 41 pacientes portadores de hepatopatia crônica de etiologia alcoólica foram randomizados para receber placebo (20 pacientes) ou colchicina (21 pacientes), avaliando sua evoluçäo clínica e dos níveis das proteínas plasmáticasalbumina, pré-albumina e transferrina por imunodifusäo radial e do tempo e atividade de protrombina pelo método de Quick modificado. RESULTADOS. Apenas 7,3 por cento dos pacientes näo completaram os 12 meses de seguimento do estudo. Näo se observaram diferenças significantes entre os grupos, no que se refere à taxa de mortalidade ou ao número de internaçöes hospitalares. Quanto aos níveis séricos protéicos, observaram-se valores significantemente superiores no grupo da colchicina do que no grupo placebo, para as médias das variaçöes percentuais dos níveis de albumina (17,9 por cento colchicina x 3,6 por cento placebo, p<0,05) e da atividade de protrombina (19,2 por cento colchicina x 2,1 por cento placebo, p<0,05). As variaçöes dos valores da pré-albumina, apesar de apresentarem o mesmo comportamento observado para os níveis de albumina e protrombina, näo atingiram significância estatística. Já os níveis de transferrina sérica näo diferiram entreos dois grupos. CONCLUSÄO. Estes resultados sugerem que a administraçäo de colchicina tenha um efeito benéfico sobre os níveis de proteínas plasmáticas nos pacientes com hepatopatia crônica de etiologia alcoólica.

[Colchicine in chronic liver disease of alcoholic etiology. Double-blind, randomized study of its effects on blood levels of plasma proteins and clinical course in patients]. / Colchicina na doença hepática crônica de etiologia alcoólica. Estudo duplo-cego, randomizado, de seus efeitos sobre os níveis séricos das proteínas plasmáticas e evolução clínica dos pacientes.

UNLABELLED: Patients with alcoholic chronic liver disease when treated with colchicine during a 12 month-period improved significantly the plasmatic levels of albumin and prothrombin when compared with a similar group of patients who took placebo. No differences in the mortality rate and in number of patients admitted at the hospital could be detected among those groups during this period. PURPOSE: To evaluate the clinical outcome and the plasmatic levels of albumin, pre-albumin, prothrombin and transferrin in patients presenting alcoholic chronic liver disease taking colchicine or placebo, during a 12-month period. METHODS: In a double-blind, randomized, controlled trial, 41 patients with alcoholic chronic liver disease were assigned to either placebo (20 patients) or a colchicine (21 patients) treatment group, assessing their clinical course (mortality rate and hospital admission) and plasmatic protein levels during a 12-month period. Albumin, pre-albumin and transferrin plasmatic levels were assessed through a immunodiffusion radial method and prothrombin time and activity was assessed by a one stage Quick modified method. RESULTS: At the end of the trial, only 7.3% of the patients were lost during follow-up. No statistical differences could be found in mortality and number of patients admitted at the hospital among placebo and colchicine groups. Comparatively to the placebo group, a significant increase in the mean of percentage variation was found in patients of the colchicine group for serum albumin levels (17.9% colchicine x 3.6% placebo, p < 0.05) and for prothrombin activity (19.2% colchicine x 2.1% placebo, p < 0.05). A similar pattern of response was found in pre-albumin serum levels, but such differences were not statistically different. No differences were found in serum transferrin levels among both groups. CONCLUSION: These results suggest that colchicine intake has a positive effect on plasmatic protein levels in patients with alcoholic chronic liver disease.

Use of ampicillin plus ranitidine for Helicobacter pylori gastritis.

1. Helicobacter pylori (formerly Campylobacter pylori) is now recognized as an etiological factor in gastritis and duodenal ulcers and probably also gastric ulcers. Eradication of the bacteria is fundamental to avoid ulcer relapse. Although bismuth salts have been shown to be effective for treatment, they are not commercially available in Brazil. 2. We report an attempt to treat patients with Helicobacter pylori-associated gastritis with ampicillin (1000 mg twice daily for one month) and compare the results with the conventional treatment used in Brazil (ranitidine, 300 mg daily for one month) and with a combination of the two drugs. We studied 44 patients with histologically confirmed gastritis and with Helicobacter pylori, who were examined at the beginning and after one month of treatment. 3. Ampicillin associated with ranitidine was better than ampicillin or ranitidine alone for the treatment of gastritis. Although ampicillin may be more efficient in patients with lower acid output we did not find a statistically significant difference between these two groups (ampicillin vs drug combination), perhaps owing to the small number of patients studied. When ampicillin was combined with ranitidine there was 25% normalization of the histological picture of the gastric mucosa. 4. We conclude that ampicillin in combination with ranitidine may be a useful treatment for Helicobacter pylori-associated gastritis.

Use of ampicilin plus ranitidine for Helicobacter pylori gastritis

Helicobacter pylori (formerly Campylobacter pylori) is now recognized as an etiological factor in gastritis and duodenal ulcers and probably also gastric ulcers. Eradication of the bacteria is fundamental to avoid ulcer relapse. Although bismuth salts have been shown to be effective for treatment, they are not commercially available in Brazil. We report an attempt to treat patients with Helicobacter pylori-associated gastritis with ampicilin (1000 mg twice daily for one month) and compare the results with the conventional treatment used in Brazil (ranitidine, 300 mg daily for one month) and with a combination of the two drugs. We studied 44 patients with histologically confirmed gastritis and with Helicobacter pylori, who were examined at the beginning and after one month of treatment. Ampicilin associated with ranitidine was better than ampicilin or ranitidine alone for the treatment of gastritis. Although ampicilin may be more efficient in patients with lower acid output we did not find a statistically significant difference between these two groups (ampicilin vs drug combination), perhaps owing to the small number of patients studied. When ampicilin was with ranitidine there was 25% normalization of the histological picture of the gastric mucosa. We conclude that ampicilin in combination with ranitidine may be a useful treatment for Helicobacter pylori-associated gastritis

Campylobacter pylori in dyspeptic patients

The presence of Campylobacter pylori in gastric mucosa of patients with dyspeptic complaints has been described. The association of the symptoms and endoscopic and histopathologic alterations with the presence of the bacterium still remains unknown. 117 patients were studied with respect to dyspeptic symptoms, endoscopic and histopathologic examinations, microbiological analysis and urease test to detect Campylobacter pylori. Campylobacter pylori was found in 77 per cent of all patients. Of these 36.8 per cent had normal gastric mucosa and 84.7 per cent presented gastritis. There was no association between the symptoms, the endoscopic and histological findings.

Hepatite tóxica causada por ketoconazol: relato de quatro casos / Ketoconazole causing toxic hepatitis: report of 4 cases

Säo descritos quatro casos de hepatite tóxica por ketoconazol. Todas eram mulheres e tomavam a droga de oito a 16 semanas (200mg/dia). O quadro clínico, em todas, foi superponível ao de uma hepatite viral. A normalizaçäo clínico-laboratorial ocorreu entre 60 e 90 dias após a suspensäo da droga, näo tendo havido óbito. Em uma das pacientes, o ketoconazol foi reintroduzido após normalizaçäo clínico-laboratorial, tendo ocorrido nova hepatite tóxica após 15 dias; a segunda suspensäo da droga foi seguida de cura da hepatite

[Toxic hepatitis caused by ketoconazole: a report of 4 cases]. / Hepatite tóxica causada por ketoconazol: relato de quatro casos.

The authors describe four cases of toxic hepatitis due to ketoconazole. All patients were female and were given the drug from 8 to 16 weeks (200mg/day). The clinical condition of the four patients was similar to that of viral hepatitis. Normalization of clinical and laboratory findings occurred 60 to 90 days after discontinuation of the drug and no patient died. One patient received ketoconazole again after her clinical and laboratory results were normalized, and a new toxic hepatitis appeared within 15 days; the second discontinuation of the drug lead to cure of the hepatitis.

Tratamento de pacientes portadores de dispepsia alta ou de úlcera peptica com preparaçöes de Espinheira-santa (Maytenus ilicifolia) / Treatment of Patients of High Dyspepsia or Peptic Ulcers with Maytenus ilicifolia Preparations

Em esquema duplo-cego, vinte e três pacientes diagnosticados como portadoes de dispepsia alta näo-ulcerosa foram alocados para receber, durante 28 dias, duas cápsulas contendo 200 mg cada de liofilizado de abafo de espinheira-santa (treze pacientes) ou cápsulas contendo açucar mascavo como placebo (onze pacientes). Apenas um paciente do grupo espinheira-santa näo terminou o tratamento contra cinco desistências do grupo placebo, sendo a diferença estatisticamente significante. O grupo espinheira-santa também apresentou melhora estatisticamente significante, em relaçäo ao grupo placebo, no que diz respeito a sintomatologia dispéptica global, e, particularmente, nos sintomas de azia e dor. Näo houve queixas de efeitos colaterais produzidos pela espinheira-santa. Vinte pacientes com úlceras pépticas, diagnosticadas endoscopicamente, passaram a receber, em esquema duplo-cego, duas cápsulas diárias com 200 mg de liofilizado de espinheira-santa (dez pacientes) ou cápsulas de palcebo (dez pacientes). Dado o número de desistências (cinco e quatro, respectivamente) e das cicatrizaçöes de úlceras terem ocorrido também no grupo placebo, os resultados näo diferiram estatisticamente

Marcadores sorológicos do virus da hepatite B e anticorpo delta em homossexuais masculinos brasileiros / Serological markers for hepatitis B virus and delta antibody in Brazilian male homosexuals

Os marcadores sorológicos do vírus B da hepatite B foram estudados em um grupo de homens homossexuais em Säo Paulo, Brasil. Encontraram-se 23% de positividade para o AgHBs nos 26 homossexuais, sendo que 81% apresentavam positividade para alguns dos marcadores do vírus B. Anticorpo anti-o näo foi detectado em nenhum caso. No grupo controle, encontrou-se 1% de positividade para o AgHBs entre 500 homens estudados

Vestibular disorders caused by defective enzyme mechanisms in the small intestine.

A group of patients suffering from long periods of unsteadiness and presenting hyperreflexia in response to torsion swing and/or caloric stimulations were found to have abnormal results in glucose and lactose tolerance tests, but normal or reduced insulin liberation. Biopsies of the jejunal mucosa have shown abnormal enzyme activity or deficiencies in transport mechanisms. The use of a diet suited to each specific deficiency resulted in a high percentage of relief from the vestibular symptoms of these patients.

Exocrine pancreatic hypersecretion in Brazilian alcoholics.

Thirty percent of alcoholic patients without clinical evidence of pancreatic or hepatic disease showed hypersecretion of pancreatic bicarbonate in all three test periods after stimulation with secretin and secretin-cholecystokinin, and an increased amount of protein in the duodenal aspirate of the first test period, probably due to ductal wash-out. This hypersecretion must be taken into account when the secretion or secretin-cholecystokinin tests of alcoholics are interpreted, and, indeed, may be useful in identifying possible early pancreatic dysfunction that precedes insufficiency and clinical symptoms.